吡格列酮对2型糖尿病患者血清脂联素和超敏C反应蛋白水平的影响  被引量:5

Effects of Pioglitazone on serum adiponectin and hs-CRP in type 2 diabetes mellitus

在线阅读下载全文

作  者:朱筱[1] 陈敏[1] 胡湘明[1] 

机构地区:[1]长沙市第四医院内分泌科,湖南长沙410006

出  处:《中国现代医学杂志》2013年第26期87-90,共4页China Journal of Modern Medicine

摘  要:目的探讨吡格列酮对2型糖尿病患者血清脂联素水平的影响。方法 52例2型糖尿病患者随机分为治疗组(n=26)和对照组(n=26),治疗组在胰岛素降糖治疗的基础上,予联合吡格列酮治疗,对照组不加用吡格列酮。总疗程为6个月。观察两组患者治疗前后胰岛素用量、空腹血糖(FBS)、餐后2 h血糖(2hPG)、空腹C肽(FCP)、血清脂联素、超敏C反应蛋白(hs-CR P)、HOMA胰岛素抵抗指数的变化情况。结果治疗6个月后,两组患者FBS、2 h PG均控制良好,治疗组血清脂联素水平较治疗前显著升高(P<0.01)、hs-CRP水平较治疗前显著降低(P<0.05),胰岛素抵抗指数(HOMA-IR)较治疗前明显改善(P<0.05);对照组血清脂联素、hs-CR P较治疗前无明显降低(P>0.05)。结论吡格列酮可明显升高2型糖尿病患者血清脂联素并降低hs-CR P水平,改善患者胰岛素抵抗,增强胰岛素敏感性。[Objective] To investigate the effects of Pioglitazone on serum adiponectin and hs-CRP in type 2 diabetes mellitus. [Methods] 52 patients with type 2 diabetes mellitus were randomly divided into treatment group (n =26) and control group (n =26). The treatment group was treated with Pioglitazone combined with insulin and the control group was treated without Pioglitazone for 6 months. Before and after treatment, insulin dosage, fasting blood sugar (FBS), postprandial 2 h glucose (2 h PG), fasting c peptide (FCP), serum adiponectin, hs-CRP and HOMA-insulin resistance index were measured. [Results] After treatment, FBS and 2 h PG were well controlled in both groups. In treatment group, a significant increase of serum adiponectin was observed (P〈0.01), and an obvious decline of serum hs-CRP was observed (P〈0.05), an improvement of HOMA-insulin resistance index was observed than before (P 〈0.05). No obvious decrease of serum adiponectin and hs-CRP were assayed in control (P〉0.05). [Conclusion] Pioglitazone could significantly improved insulin resistance in type 2 diabetic patients by increasing serum adiponectin and decreasing serum hs-CRP.

关 键 词:吡格列酮 糖尿病 脂联素 

分 类 号:R578.1[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象